西蒙胶囊促血小板生成与长毒研究
|
摘要
研究背景
血小板减少性紫癜为常见病、多发病,该病的发病机制主要为自身免疫机制失调,临床表现为外周血小板减少。目前,该病的药物治疗为皮质类固醇激素和免疫抑制剂,但长期应用不良反应较多,且停药后易复发。西蒙为旋花科甘薯属植物,巴西民间证明,西蒙薯块具有止血作用。西蒙胶囊是用西蒙干叶提取物制成,本实验对西蒙胶囊升血小板作用及安全性进行了研究。
方法
家兔注射豚鼠抗兔血小板血清诱发免疫性血小板减少症模型;大鼠注射兔抗大鼠血小板血清建立大免疫性血小板减少症动物模型;辐照小鼠致血小板减少模型;家兔注射花生四烯酸诱导血小板减少症模型。血小板、红细胞、白细胞、巨核细胞计数;比色法测定血红蛋白,血小板用酶联免疫吸附法(ELISA)测定血小板相关抗体IgG(PAIgG)。
在体犬与大鼠观察了其长期毒性。
结果
结果显示,在注射豚鼠抗兔血小板血清引起的家兔免疫性血小板减少模型,3个剂量(分别为0.23、0.46、0.92g/kg)的西蒙胶囊预防或治疗给药均能升高血小板,降低巨核细胞数和PAIgG水平。在注射兔抗大鼠血小板血清引起大鼠免疫性血小板减少模型,西蒙胶囊(剂量分别为0.44、0.88、1.76g/kg)能显著升高血小板,但不影响红细胞和白细胞数。在辐照小鼠所致的血小板减少模型,西蒙胶囊(剂量分别为0.64、1.27、2.55g/kg)能显著升高血小板,也能升高白细胞数、血红蛋白水平;在家兔注射花生四烯酸诱导血小板减少模型,西蒙胶囊(剂量分别为0.23g、0.46、0.92g/kg)能升高血小板和白细胞数。
在体大鼠灌胃给予西蒙胶囊(4.90、2.45、1.22g/kg·d),连续13周和恢复期,血液细胞学、血液生化学、器官形态学无明显病理学改变。同样,在体Beagle犬灌胃西蒙(3.50、1.75、0.88g/kg·d),连续26周和恢复期,血液细胞学、血液生化学、器官形态学也无明显病理学改变。
结论
在免疫、辐身或化学药物所致血小板减少模型,西蒙胶囊能显著升高血小板数。
在体动物(大鼠、犬)长期给予西蒙胶囊,未见明显毒性作用。
Background
Thrombocytopenia is a common and frequently occurring disease, which is thought to be related to the autoimmune disorder, and with clinical symptom of decreased platelet count in peripheral blood. Classic treatment of thrombocytopenia is through drugs like glucocorticoids or immunosuppressor, but the adverse effects caused by the long-term usage of those drugs are quite common, and the disease recrudescence frequently happens after medicine withdrawn. Simon belongs to Ipomoea category of Convolvulaceae section, and the traditional usage of simon in Brazil has proved its effect on hemostasis. In the present study, we explored the effect of simon capsules on elevating platelet count and evaluated the safety of the drug.
METHODS
Immune thrombocytopenia rabbit model was induced by injection of guinea pig serum of anti-rabbit-platelet in rabbits. Immune thrombocytopenia rat model was induced by injection of rabbit serum of anti-rat-platelet in rats. Thrombocytopenia mouse model was induced by radiation in mice. Thrombocytopenia rabbit model was induced by injection of arachidonic acid in rabbits. Platelets, red blood cells, white blood cells and megakaryoblastic cells were counted, hemoglobin was measured through colorimetric method, and platelet related IgG (PAIgG) were measured through ELISA method.
Long-term toxicology of Simon capsules was evaluated in bothdogs and rats.
RESULTS
Pretreatment or treatment with simon capsules increased platelets, while decreased megakaryoblastic cells and PAIgG level in the immune thrombocytopenia rabbit model. In the immune thrombocytopenia rat model, simon capsules significantly increased platelets count, but had no effect on red blood cells and white blood cells. In the thrombocytopenia mouse model, simon capsules significantly increased platelets count, and elevated white blood cells and hemoglobin level. In the thrombocytopenia rabbit model, simon capsules increased platelets and white blood cells.
In rats and Beagle dogs, orally administration of simon capsules didn't induce obvious pathologic changes in routine blood count, biochemistry blood analysis and organic morphology for the continuing 13 weeks treatment and during the recovery period.
CONCLUSION
Simon capsules significantly increase platelet count in thrombocytopenia models induced by immune response, radiation or chemical compounds.
Long-term treatment with simon capsules does not induce obvious toxicology effects.
血小板减少性紫癜为常见病、多发病,该病的发病机制主要为自身免疫机制失调,临床表现为外周血小板减少。目前,该病的药物治疗为皮质类固醇激素和免疫抑制剂,但长期应用不良反应较多,且停药后易复发。西蒙为旋花科甘薯属植物,巴西民间证明,西蒙薯块具有止血作用。西蒙胶囊是用西蒙干叶提取物制成,本实验对西蒙胶囊升血小板作用及安全性进行了研究。
方法
家兔注射豚鼠抗兔血小板血清诱发免疫性血小板减少症模型;大鼠注射兔抗大鼠血小板血清建立大免疫性血小板减少症动物模型;辐照小鼠致血小板减少模型;家兔注射花生四烯酸诱导血小板减少症模型。血小板、红细胞、白细胞、巨核细胞计数;比色法测定血红蛋白,血小板用酶联免疫吸附法(ELISA)测定血小板相关抗体IgG(PAIgG)。
在体犬与大鼠观察了其长期毒性。
结果
结果显示,在注射豚鼠抗兔血小板血清引起的家兔免疫性血小板减少模型,3个剂量(分别为0.23、0.46、0.92g/kg)的西蒙胶囊预防或治疗给药均能升高血小板,降低巨核细胞数和PAIgG水平。在注射兔抗大鼠血小板血清引起大鼠免疫性血小板减少模型,西蒙胶囊(剂量分别为0.44、0.88、1.76g/kg)能显著升高血小板,但不影响红细胞和白细胞数。在辐照小鼠所致的血小板减少模型,西蒙胶囊(剂量分别为0.64、1.27、2.55g/kg)能显著升高血小板,也能升高白细胞数、血红蛋白水平;在家兔注射花生四烯酸诱导血小板减少模型,西蒙胶囊(剂量分别为0.23g、0.46、0.92g/kg)能升高血小板和白细胞数。
在体大鼠灌胃给予西蒙胶囊(4.90、2.45、1.22g/kg·d),连续13周和恢复期,血液细胞学、血液生化学、器官形态学无明显病理学改变。同样,在体Beagle犬灌胃西蒙(3.50、1.75、0.88g/kg·d),连续26周和恢复期,血液细胞学、血液生化学、器官形态学也无明显病理学改变。
结论
在免疫、辐身或化学药物所致血小板减少模型,西蒙胶囊能显著升高血小板数。
在体动物(大鼠、犬)长期给予西蒙胶囊,未见明显毒性作用。
Background
Thrombocytopenia is a common and frequently occurring disease, which is thought to be related to the autoimmune disorder, and with clinical symptom of decreased platelet count in peripheral blood. Classic treatment of thrombocytopenia is through drugs like glucocorticoids or immunosuppressor, but the adverse effects caused by the long-term usage of those drugs are quite common, and the disease recrudescence frequently happens after medicine withdrawn. Simon belongs to Ipomoea category of Convolvulaceae section, and the traditional usage of simon in Brazil has proved its effect on hemostasis. In the present study, we explored the effect of simon capsules on elevating platelet count and evaluated the safety of the drug.
METHODS
Immune thrombocytopenia rabbit model was induced by injection of guinea pig serum of anti-rabbit-platelet in rabbits. Immune thrombocytopenia rat model was induced by injection of rabbit serum of anti-rat-platelet in rats. Thrombocytopenia mouse model was induced by radiation in mice. Thrombocytopenia rabbit model was induced by injection of arachidonic acid in rabbits. Platelets, red blood cells, white blood cells and megakaryoblastic cells were counted, hemoglobin was measured through colorimetric method, and platelet related IgG (PAIgG) were measured through ELISA method.
Long-term toxicology of Simon capsules was evaluated in bothdogs and rats.
RESULTS
Pretreatment or treatment with simon capsules increased platelets, while decreased megakaryoblastic cells and PAIgG level in the immune thrombocytopenia rabbit model. In the immune thrombocytopenia rat model, simon capsules significantly increased platelets count, but had no effect on red blood cells and white blood cells. In the thrombocytopenia mouse model, simon capsules significantly increased platelets count, and elevated white blood cells and hemoglobin level. In the thrombocytopenia rabbit model, simon capsules increased platelets and white blood cells.
In rats and Beagle dogs, orally administration of simon capsules didn't induce obvious pathologic changes in routine blood count, biochemistry blood analysis and organic morphology for the continuing 13 weeks treatment and during the recovery period.
CONCLUSION
Simon capsules significantly increase platelet count in thrombocytopenia models induced by immune response, radiation or chemical compounds.
Long-term treatment with simon capsules does not induce obvious toxicology effects.
引文
[1]张之南,单渊东.协和血液病学[M].北京:中国协和医科大学出版社,2004,626-640.
[2]George JN and Rizvi MA.Indiopathic thrombocytopenic purpura.In:Beutler E,Lichtman MA,Coller BS,et al eds.Williams Hematology.6th ED,New York:McGraw-Hill,2001,1513-1548.
[3]Watanabe A,Kakihara T,Yamamoto K,et al.High-dose dexamethasone therapy for a 14-month-old boy with refractory idiopathic thrombocytopenic purpura[J].Acta Paediatr Jpn Jun.1997,39(3):368-370
[4]Wali YA,Al Lamki Z,Shah W,et al.Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura[J].Pediatr Hematol Oncol.2002,19(5):329-335
[5]Godeau B,Zini JM,Schaefer A,et al.High-dose methylprednisolone is an alternative treatment for adults with.autoimmune thrombocytopenic purpura refractory to intravenous immunoglobulins and oral corticosteroids[J].Am J Hematol Apr.1995,48(4):282-284
[6]Smak Gregoor PJH,van Gelder T,van Besouw NM,van der Mast B J,Uzermans JN,Weimar W.Randomised study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction[J].Transplantation.2000,70(1):143-148
[7]Reiner A.Idiopathic thrombocytopenic purpura[J].Blood,1995,85:351-358
[8]Emilia G,Morselli M,Luppi M,et al.Long-term salvage therapy with cyclosporinA in refractory idiopathic thrombocytopenic purpura.Blood.2002,99(4):1482-1485
[9]Howard J,Hoffbrand AV,Prentice HG,et al,Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura[J].Br J Haematol.2002,117(3):712 -715.
[10]SV Strother,KS Zuckerman,AF LoBuglio.Colchicine therapy for refractory idiopathic thrombocytopenic purpura[J].Arch Intern Med,1984,144(11):2198-2200
[11]Kamiyama M,Yoshimura Y,Chen K,et al.Effect of intravenous immunoglobulin on inhibition of fibrinogen binding to platelets by sera from patients with immune thrombocytopenia[J].Am J Hematol Oct.1993,44(2):77-84
[12]Semple JW,Allen D,Rutherford M,et al.Anti-D(VinRho SD)treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production[J].Am J Hematol Mar.2002,69(3):225-227
[13]Alan YS.Efficacy of danazol in hematologic disorders[J].Acta Haematol,1990,84(3):122-129
[14]Godeau B,Oksenhendler E,Bierling P.Dapsone for autoimmune thrombocytopenic purpura[J].Am J Hematol,1993,44(1):70-72
[15]Hernandez F.Dapsone for autoimmune thrombocytopenic purpura[J].Br J Haematol,1995,90(2):473-475
[16]Meeker ND,Goldsby R,Terrill KR,et al.Dapsone therapy for children with immune thrombocytopenic purpura[J].J Pediatr Hematol Oncol,2003,25(2):173-175
[17]Sekreta CM,Baker DE.Interferon alfa therapy in adults with chronic idiopathic thrombocytopenic purpura[J].Ann Pharmacother Oct,1996,30(10):1176-1179
[18]DMci B,Bosnak M,Kara IH,et al.Interferon-alpha therapy in idiopathic thrombocytopenic purpura[J].Pediatr Int,2001,43(6):577-580
[19]展昭民,王志平,陈立君,等.玳瑁紫疲宁治疗原发性血小板减少性紫癜的研究[J].中医杂志.1994,35(9):541-543.
[20]靳丽丽,陶淑春,孟根东.紫癜冲剂治疗原发性血小板减少性紫癜78例[J].辽宁中医杂志,1999,26(6):253-254
[21]生部药政局:中药新药研究指南1994年
[22]詹文彦等,免疫性血小板减少症家兔动物模型的对立,中国实验临床免疫学杂志,1992:4(5):17-20
[23]蒋文明等,大鼠免疫性血小板减少模型的研究,中国实验动物学报,1996:4(2):104-107
[24]药理学实验指南--新药发现和药理学评价,[德]H.G沃格尔[美]W.H.沃格尔编著,2001:P211-213,科学出版社
[25]李仪奎:中药药理实验方法学,上海科学技术出版社1991:P305
[26]潘善庆等,生血灵补血作用的研究,湖南中医杂志,1999:15(5):56
[27]张源慧.原发性血小板减少性紫癜的发病机理[J].中华血液学杂志,1990,(4):214.
[28]Mc Millan R.chronic idiopathic thrombocytopenic purpura[J].N Engl J Med,1981,304:1135.
[29]孙凤,韩晶,郭春兰,等.紫茜胶囊对原发性血小板减少性紫癜鼠外周血的影响研究.中医药信息.2006,23(1):61-62.
[30]徐红,王开贞,高尔,等.升板合剂提升血小板作用的实验研究.中国中医药科技,2006,13(5):313-314.
[31]迟文,徐静,谭巍,等.杨梅多酚对大、小鼠血小板损伤的保护作用.中国药房,2002,13(1):16-17.
[32]李华,宫传,邝荔香.血康口服液对家兔免疫性血小板减少症的治疗作用.安徽卫生职业技术学院学报,2003,2(3):53-54.
[33]王安行,朱家谷.血康胶囊升血小板和白细胞作用的实验研究.浙江中西医结合杂志,1998,8(3):144-145.
[34]刘宏潇,张雅丽,田维毅,等.加减归脾汤对脾不统血型ITP小鼠药效学及免疫学作用机制研究.中国中医基础医学杂志,2002,8(5):67-69.
[35]许勇钢,杨晓红,王洪志,等.金薯叶止血合剂对ITP模型动物的治疗作用.中国中医基础医学杂志.2006,12(9):647-649.
[36]傅汝林,刘为民,张雅丽,等.归脾冲剂对免疫性血小板减少性紫癜动物模型实验研究.中医药学刊,2001,19(4):312-313.
[37]范颖,马骥,陶淑春,等.紫癜颗粒对ITP模型小鼠外周血细胞因子IL-2、IL-6、IL-8的影响.北京中医药大学学报,2004,27(6):44-46.
[38]范颖,马骥,陶淑春,等.紫癜颗粒对ITP模型小鼠外周血小板的影响.中药新药与临床药理,2004,15(3):158-161.
[39]范颖,马骥,陶淑春.紫癜颗粒对ITP模型小鼠血小板、T亚群及细胞因子的影响.中国实验方剂学杂志.2005,11(4):39-41.
[40]谭桂山、徐平声、戴智勇.引种巴西甘薯叶化学成分研究(I).天然产物研究与开发,1995,7(4)35-37
[1]张之南,单渊东.协和血液病学[M].北京:中国协和医科大学出版社,2004,626-640.
[2]George JN and Rizvi MA.Indiopathic thrombocytopenic purpura.In:Beutler E,Lichtman MA,Coller BS,et al eds.Williams Hematology.6th ED,New York:McGraw-Hill,2001,1513-1548.
[3]McCrae KR and Cines D.Thrombotic thrombocytopenic purpura- hemolytic uremic syndrome.In:Colman RW,Hirsh J,Marder VJ,et al eds.Hemostasis and thrombosis:basic principle and clinical practice.4th ed,Philadelphia:Lippincott Williams and Wilkins,2001,1235-1257.
[4]De Sauvage F J,Hass PE,Spencer SD,et al.Stimulation of megakaryocytopoiesis and thrombopoesis by the c-mpl ligand[J].Nature.1994,369(6481):533-538.
[5]欧瑞明,陈运贤,钟雪云.血小板生成因子的研究进展[J].中国病理生理杂志.2001,17(3):346-349
[6]Sola MC,Du Y,Hutson AD.Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non- thrombocytopenic neonates to recombinant thrombopoietin[J].Br.J Haematol.2000,110(2):449-453
[7]Vadhan-Raj S,Murray LJ,Bueso-Ramos C,et al.Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin n patients with cancer[J].Ann Int Med,1997,126:673-681
[8]Vadhan-Raj S,Verschraegen C,McGarry L,et al.Recombinant human thrombopoietin(rhTPO)attenuates high-dose carboplatin(C)-induced thrombocy-topenia in patients with gynecologic malignancy[J].Blood,1997,90:580a (suppl)
[9]Fanucchi M,Glaspy J,Crawfork J,et al.Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer[J].N Engl J Med.1997,336:404-409
[10]Vadhan-Raj S.Phase I-I I in vestigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy(CT) with adriamycin(A) and ifosfamide(I) [J]. Blood. 1996, 88: 448a(suppl)
[11] Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies[J]. Blood. 2002,100(10): 3457-3461
[12] O Malley CJ, Rasko JEJ, Basser RJ, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to human stimulates the production of functional platelers than show no evidence of in vivo activation[J]. Blood. 1996, 88: 3288-3298.
[13] Wolff SN. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study[J]. Bone Marrow Transplant. 2001,27(3):261-268
[14] Paul S R, Bennett F, Calvetti J A, et al. Molecular cloning of cDNA encoding interleukin-11, a stromal cell-derived lympopoietic and hematopoietic cytokine. Proc. Natl Acad Sci. 1990, 87:7512—7516
[15] Morris J C, Neben S, Bennett F, et al. Molecular cloning and characterization of murine interleukin-11[J]. Exp Hematol. 1996,24:1369—1376
[16]朱勇．白细胞介索-11[J]．国外医学免疫分册．2004,6：281-285．
[17] MaeshimaK, Takahashi T, NakahiraK, et al. A protective role of interleukin 11 on hepatic inj ury in acute endotoxemia[J]. Shock. 2004, 21 (2): 134-138
[18] Wen CY, Ito M, Matsuu M, et al. Mechanism of the antiulcerogenic effect of IL-11 on acetic acid-induced gastric ulcer in rats[J]. Life Sci. 2002, 70(25):2997-3005
[19] Chang M, Suen Y, Meng G, et al. Differential mechamisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocy-topenia insight into the regulation of production[J]. Blood, 2001, 88(9):3354-3362
[20] Zondor SD, George JN, Medina PJ. Treatment of drug-induced thrombocy- topenia[J]. Expert Opin Drug Say. 2002,1(2): 173—180.
[21] Tan H, Dan G, Gong H, et al. Purification and characterization of recombinant truncated human interleukin-11 expressed as fusion protein in Escherichia coli[J]. Biotechnol Lett. 2005,27(13): 905-910
[22]Kaye JA.FDA licensure of NEUMEGA to prevent severe chemotherapy induced thrombocytopenia[J].Stem Cells.1998,16(2):207-223
[23]Cotreau MM,Stonis L,Strahs A,et al.A multiple-dose,salty,tolerability,pharmacokinetics and pharmacodynamic study of recombinant human interleukin-11(oprelvekin)[J].Biopharm Drug Dispos,2004,25(7):291-296.
[24]Sitaraman SV,Gewirtz AT.Oprelvekin.Genetics Institute[J].Curt Opin lnvestig Drugs.2001,2(10):1395-1400
[25]柴彪新,刘秀文,汤仲明.药代动学研究用蛋白质多肽药物的放射性标记、分离纯化和鉴定[J].中国核医学杂志.2003,18(1):53-54
[26]Cantor SB,Elting LS,Hudson DV,et al.Pharmacoeconomic analysis of oprelvekin(recombinant human interleukin-11)for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy[J].Cancer,2003,97(12):3099-3106
[27]钟立业,陈运贤,钟雪云,等.血小板生成素Ⅱ体内生物话性研究[J].中国病理生理杂志.2001,17(4):346-349
[28]钟立业,林伟,杜欣,等.血小板生成素Ⅱ体内生物生物活性及其对小鼠死始终如一“亡率的影响[J].中国肿瘤临床与康复,2001,8(增刊):26-28
[29]Jeffrey MC.Current issues with platelet transfusion in patients with cancer[J].Seminars in Hematology,2000,37(Supp14):3-10
[30]Kudoh S.Sawa T.Kuribara N.et al.Phase Ⅱ study of recombine human interleukin 3 adaministration following carboplatin and etoposide chemotherapy in small cell lung cancer patients SDZ ILE 9ud IL-3 study.Cancer Chemother Pharmacol.1996,38(Suppl):389-395
[31]Hofstra LS,Knstensen GB,Willomse PH.et at.Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow'depression during first-line chemotherapy for ovarian carcinoma[J].J Clin Oncol.1998,16(10):3335-3339
[32]Crawford J.Uu D.Erwin R.et al.A phase I trial of recombinant methnoyl human stem cell factor(SCF)in patients with advanced non-mall cell lung carcinoma[J].Proc Am Soc Clin Oncol.1993,12:135-146
[33]Rinechat J.Hersh E.Issel B.et al.Phase I trial of recombinant human interleukin-1β(rhIL-1β),carboplatin and etoposide in patients with solid cancer:southwest oncology group study 8940[J].Cancer Invest.1997,15(5):403-410
[34]钟立业,陈运贤,林伟.血小板减少症治疗的研究进展[J].血栓与止血学,2001,7(4):178-180
[35]Watanabe A,Kakihara T,Yamamoto K,et al.High-dose dexamethasone therapy for a 14-month-old boy with refractory idiopathic thrombocytopenic purpura[J].Acta Paediatr Jpn Jun.1997,39(3):368-370
[36]Wali YA,Al Lamki Z,Shah W,et al.Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura[J].Pediatr Hematol Oncol.2002,19(5):329-335
[37]Godeau B,Zini JM,Schaefer A,et al.High-dose methylprednisolone is an alternative treatment for adults with autoimmune thrombocytopenic purpura refractory to intravenous immunoglobulins and oral corticosteroids[J].Am J Hematol Apr.1995,48(4):282-284
[38]Smak Gregoor PJH,van Gelder T,van Besouw NM,van der Mast BJ,Uzermans JN,Weimar W.Randomised study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction[J].Transplantation.2000,70(1):143-148
[39]Reiner A.Idiopathic thrombocytopenic purpura[J].Blood,1995,85:351-358
[40]Emilia G,Morselli M,Luppi M,et al.Long-term salvage therapy with cyclosporinA in refractory idiopathic thrombocytopenic purpura.Blood.2002,99(4):1482-1485
[41]Howard J,Hoffbrand AV,Prentice HG,et al,Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura[J].Br J Haematol.2002,117(3):712-715.
[42]沈建咸,郭瑞官,李健,等.四种方案治疗难治性原发性血小板减少性紫疲的疗效[J].福建医学院学报,1996,30(1):69-70
[43]SV Strother,KS Zuckerman,AF LoBuglio.Colchicine therapy for refractory idiopathic thrombocytopenic purpura[J].Arch Intern Med,1984,144(11):2198-2200
[44]Kamiyama M,Yoshimura Y,Chen K,et al.Effect of intravenous immunoglobulin on inhibition of fibrinogen binding to platelets by sera from patients with immune thrombocytopenia[J].Am J Hematol Oct.1993,44(2):77 -84
[45]Semple JW,Allen D,Rutherford M,et al.Anti-D(VinRho SD)treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production[J].Am J Hematol Mar.2002,69(3):225-227
[46]刘义.达那唑的免疫调节作用[J].国外医学妇产科学分册,1997,24(1):12
[47]Ahn YS.Efficacy of danazol in hematologic disorders[J].Acta Haematol,1990,84(3):122-129
[48]Godeau B,Oksenhendler E,Bierling P.Dapsone for autoimmune thrombocytopenic purpura[J].Am J Hematol,1993,44(1):70-72
[49]Hernandez F.Dapsone for autoimmune thromboeytopenic purpura[J].Br J Haematol,1995,90(2):473-475
[50]Meeker ND,Goldsby R,Terrill KR,et al.Dapsone therapy for children with immune thrombocytopenic purpura[J].J Pediatr Hematol Oncol,2003,25(2):173-175
[51]Sekreta CM,Baker DE.Interferon alfa therapy in adults with chronic idiopathic thrombocytopenic purpura[J].Ann Pharmacother Oct,1996,30(10):1176-1179
[52]DMci B,Bosnak M,Kara IH,et al.Interferon-alpha therapy in idiopathic thrombocytopenic purpura[J].Pediatr Int,2001,43(6):577-580
[53]Donato H,Kohan R,Piton A,et al.Alpha-interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura[J].J Pediatr Hematol Oncol,2001,23(9):598-603
[54]陈秋生,沈志祥,韩忠朝,等.肝素增强血小板生成素刺激巨核细胞生成[J].中华血液学杂志,1999,20(9):462-464
[55]沈志祥,李军民,王振义,等.肝素治疗慢性特发性血小板减少性紫疲的初步疗效观察[J].中华血液学杂志,1995,16(4):196-197
[56]展昭民,王志平,陈立君,等.玳瑁紫疲宁治疗原发性血小板减少性紫癜的研究[J].中医杂志.1994,35(9):541-543.
[57]靳丽丽,陶淑春,孟根东.紫癜冲剂治疗原发性血小板减少性紫癜78例[J].辽宁中医杂志,1999,26(6):253-254
[58]黄建.自拟消癜饮治疗原发性紫疲86例[J].湖南中医药导报,1998,4(11):26-27
[59]布仁巴圈,孙海山,刘立杰.蒙药血宝丸治疗慢性血小板减少性紫癜30例疗效观察[J].中国民族医药杂志,1998,4(4):8-9
[2]George JN and Rizvi MA.Indiopathic thrombocytopenic purpura.In:Beutler E,Lichtman MA,Coller BS,et al eds.Williams Hematology.6th ED,New York:McGraw-Hill,2001,1513-1548.
[3]Watanabe A,Kakihara T,Yamamoto K,et al.High-dose dexamethasone therapy for a 14-month-old boy with refractory idiopathic thrombocytopenic purpura[J].Acta Paediatr Jpn Jun.1997,39(3):368-370
[4]Wali YA,Al Lamki Z,Shah W,et al.Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura[J].Pediatr Hematol Oncol.2002,19(5):329-335
[5]Godeau B,Zini JM,Schaefer A,et al.High-dose methylprednisolone is an alternative treatment for adults with.autoimmune thrombocytopenic purpura refractory to intravenous immunoglobulins and oral corticosteroids[J].Am J Hematol Apr.1995,48(4):282-284
[6]Smak Gregoor PJH,van Gelder T,van Besouw NM,van der Mast B J,Uzermans JN,Weimar W.Randomised study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction[J].Transplantation.2000,70(1):143-148
[7]Reiner A.Idiopathic thrombocytopenic purpura[J].Blood,1995,85:351-358
[8]Emilia G,Morselli M,Luppi M,et al.Long-term salvage therapy with cyclosporinA in refractory idiopathic thrombocytopenic purpura.Blood.2002,99(4):1482-1485
[9]Howard J,Hoffbrand AV,Prentice HG,et al,Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura[J].Br J Haematol.2002,117(3):712 -715.
[10]SV Strother,KS Zuckerman,AF LoBuglio.Colchicine therapy for refractory idiopathic thrombocytopenic purpura[J].Arch Intern Med,1984,144(11):2198-2200
[11]Kamiyama M,Yoshimura Y,Chen K,et al.Effect of intravenous immunoglobulin on inhibition of fibrinogen binding to platelets by sera from patients with immune thrombocytopenia[J].Am J Hematol Oct.1993,44(2):77-84
[12]Semple JW,Allen D,Rutherford M,et al.Anti-D(VinRho SD)treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production[J].Am J Hematol Mar.2002,69(3):225-227
[13]Alan YS.Efficacy of danazol in hematologic disorders[J].Acta Haematol,1990,84(3):122-129
[14]Godeau B,Oksenhendler E,Bierling P.Dapsone for autoimmune thrombocytopenic purpura[J].Am J Hematol,1993,44(1):70-72
[15]Hernandez F.Dapsone for autoimmune thrombocytopenic purpura[J].Br J Haematol,1995,90(2):473-475
[16]Meeker ND,Goldsby R,Terrill KR,et al.Dapsone therapy for children with immune thrombocytopenic purpura[J].J Pediatr Hematol Oncol,2003,25(2):173-175
[17]Sekreta CM,Baker DE.Interferon alfa therapy in adults with chronic idiopathic thrombocytopenic purpura[J].Ann Pharmacother Oct,1996,30(10):1176-1179
[18]DMci B,Bosnak M,Kara IH,et al.Interferon-alpha therapy in idiopathic thrombocytopenic purpura[J].Pediatr Int,2001,43(6):577-580
[19]展昭民,王志平,陈立君,等.玳瑁紫疲宁治疗原发性血小板减少性紫癜的研究[J].中医杂志.1994,35(9):541-543.
[20]靳丽丽,陶淑春,孟根东.紫癜冲剂治疗原发性血小板减少性紫癜78例[J].辽宁中医杂志,1999,26(6):253-254
[21]生部药政局:中药新药研究指南1994年
[22]詹文彦等,免疫性血小板减少症家兔动物模型的对立,中国实验临床免疫学杂志,1992:4(5):17-20
[23]蒋文明等,大鼠免疫性血小板减少模型的研究,中国实验动物学报,1996:4(2):104-107
[24]药理学实验指南--新药发现和药理学评价,[德]H.G沃格尔[美]W.H.沃格尔编著,2001:P211-213,科学出版社
[25]李仪奎:中药药理实验方法学,上海科学技术出版社1991:P305
[26]潘善庆等,生血灵补血作用的研究,湖南中医杂志,1999:15(5):56
[27]张源慧.原发性血小板减少性紫癜的发病机理[J].中华血液学杂志,1990,(4):214.
[28]Mc Millan R.chronic idiopathic thrombocytopenic purpura[J].N Engl J Med,1981,304:1135.
[29]孙凤,韩晶,郭春兰,等.紫茜胶囊对原发性血小板减少性紫癜鼠外周血的影响研究.中医药信息.2006,23(1):61-62.
[30]徐红,王开贞,高尔,等.升板合剂提升血小板作用的实验研究.中国中医药科技,2006,13(5):313-314.
[31]迟文,徐静,谭巍,等.杨梅多酚对大、小鼠血小板损伤的保护作用.中国药房,2002,13(1):16-17.
[32]李华,宫传,邝荔香.血康口服液对家兔免疫性血小板减少症的治疗作用.安徽卫生职业技术学院学报,2003,2(3):53-54.
[33]王安行,朱家谷.血康胶囊升血小板和白细胞作用的实验研究.浙江中西医结合杂志,1998,8(3):144-145.
[34]刘宏潇,张雅丽,田维毅,等.加减归脾汤对脾不统血型ITP小鼠药效学及免疫学作用机制研究.中国中医基础医学杂志,2002,8(5):67-69.
[35]许勇钢,杨晓红,王洪志,等.金薯叶止血合剂对ITP模型动物的治疗作用.中国中医基础医学杂志.2006,12(9):647-649.
[36]傅汝林,刘为民,张雅丽,等.归脾冲剂对免疫性血小板减少性紫癜动物模型实验研究.中医药学刊,2001,19(4):312-313.
[37]范颖,马骥,陶淑春,等.紫癜颗粒对ITP模型小鼠外周血细胞因子IL-2、IL-6、IL-8的影响.北京中医药大学学报,2004,27(6):44-46.
[38]范颖,马骥,陶淑春,等.紫癜颗粒对ITP模型小鼠外周血小板的影响.中药新药与临床药理,2004,15(3):158-161.
[39]范颖,马骥,陶淑春.紫癜颗粒对ITP模型小鼠血小板、T亚群及细胞因子的影响.中国实验方剂学杂志.2005,11(4):39-41.
[40]谭桂山、徐平声、戴智勇.引种巴西甘薯叶化学成分研究(I).天然产物研究与开发,1995,7(4)35-37
[1]张之南,单渊东.协和血液病学[M].北京:中国协和医科大学出版社,2004,626-640.
[2]George JN and Rizvi MA.Indiopathic thrombocytopenic purpura.In:Beutler E,Lichtman MA,Coller BS,et al eds.Williams Hematology.6th ED,New York:McGraw-Hill,2001,1513-1548.
[3]McCrae KR and Cines D.Thrombotic thrombocytopenic purpura- hemolytic uremic syndrome.In:Colman RW,Hirsh J,Marder VJ,et al eds.Hemostasis and thrombosis:basic principle and clinical practice.4th ed,Philadelphia:Lippincott Williams and Wilkins,2001,1235-1257.
[4]De Sauvage F J,Hass PE,Spencer SD,et al.Stimulation of megakaryocytopoiesis and thrombopoesis by the c-mpl ligand[J].Nature.1994,369(6481):533-538.
[5]欧瑞明,陈运贤,钟雪云.血小板生成因子的研究进展[J].中国病理生理杂志.2001,17(3):346-349
[6]Sola MC,Du Y,Hutson AD.Dose-response relationship of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non- thrombocytopenic neonates to recombinant thrombopoietin[J].Br.J Haematol.2000,110(2):449-453
[7]Vadhan-Raj S,Murray LJ,Bueso-Ramos C,et al.Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin n patients with cancer[J].Ann Int Med,1997,126:673-681
[8]Vadhan-Raj S,Verschraegen C,McGarry L,et al.Recombinant human thrombopoietin(rhTPO)attenuates high-dose carboplatin(C)-induced thrombocy-topenia in patients with gynecologic malignancy[J].Blood,1997,90:580a (suppl)
[9]Fanucchi M,Glaspy J,Crawfork J,et al.Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer[J].N Engl J Med.1997,336:404-409
[10]Vadhan-Raj S.Phase I-I I in vestigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy(CT) with adriamycin(A) and ifosfamide(I) [J]. Blood. 1996, 88: 448a(suppl)
[11] Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies[J]. Blood. 2002,100(10): 3457-3461
[12] O Malley CJ, Rasko JEJ, Basser RJ, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to human stimulates the production of functional platelers than show no evidence of in vivo activation[J]. Blood. 1996, 88: 3288-3298.
[13] Wolff SN. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study[J]. Bone Marrow Transplant. 2001,27(3):261-268
[14] Paul S R, Bennett F, Calvetti J A, et al. Molecular cloning of cDNA encoding interleukin-11, a stromal cell-derived lympopoietic and hematopoietic cytokine. Proc. Natl Acad Sci. 1990, 87:7512—7516
[15] Morris J C, Neben S, Bennett F, et al. Molecular cloning and characterization of murine interleukin-11[J]. Exp Hematol. 1996,24:1369—1376
[16]朱勇．白细胞介索-11[J]．国外医学免疫分册．2004,6：281-285．
[17] MaeshimaK, Takahashi T, NakahiraK, et al. A protective role of interleukin 11 on hepatic inj ury in acute endotoxemia[J]. Shock. 2004, 21 (2): 134-138
[18] Wen CY, Ito M, Matsuu M, et al. Mechanism of the antiulcerogenic effect of IL-11 on acetic acid-induced gastric ulcer in rats[J]. Life Sci. 2002, 70(25):2997-3005
[19] Chang M, Suen Y, Meng G, et al. Differential mechamisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocy-topenia insight into the regulation of production[J]. Blood, 2001, 88(9):3354-3362
[20] Zondor SD, George JN, Medina PJ. Treatment of drug-induced thrombocy- topenia[J]. Expert Opin Drug Say. 2002,1(2): 173—180.
[21] Tan H, Dan G, Gong H, et al. Purification and characterization of recombinant truncated human interleukin-11 expressed as fusion protein in Escherichia coli[J]. Biotechnol Lett. 2005,27(13): 905-910
[22]Kaye JA.FDA licensure of NEUMEGA to prevent severe chemotherapy induced thrombocytopenia[J].Stem Cells.1998,16(2):207-223
[23]Cotreau MM,Stonis L,Strahs A,et al.A multiple-dose,salty,tolerability,pharmacokinetics and pharmacodynamic study of recombinant human interleukin-11(oprelvekin)[J].Biopharm Drug Dispos,2004,25(7):291-296.
[24]Sitaraman SV,Gewirtz AT.Oprelvekin.Genetics Institute[J].Curt Opin lnvestig Drugs.2001,2(10):1395-1400
[25]柴彪新,刘秀文,汤仲明.药代动学研究用蛋白质多肽药物的放射性标记、分离纯化和鉴定[J].中国核医学杂志.2003,18(1):53-54
[26]Cantor SB,Elting LS,Hudson DV,et al.Pharmacoeconomic analysis of oprelvekin(recombinant human interleukin-11)for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy[J].Cancer,2003,97(12):3099-3106
[27]钟立业,陈运贤,钟雪云,等.血小板生成素Ⅱ体内生物话性研究[J].中国病理生理杂志.2001,17(4):346-349
[28]钟立业,林伟,杜欣,等.血小板生成素Ⅱ体内生物生物活性及其对小鼠死始终如一“亡率的影响[J].中国肿瘤临床与康复,2001,8(增刊):26-28
[29]Jeffrey MC.Current issues with platelet transfusion in patients with cancer[J].Seminars in Hematology,2000,37(Supp14):3-10
[30]Kudoh S.Sawa T.Kuribara N.et al.Phase Ⅱ study of recombine human interleukin 3 adaministration following carboplatin and etoposide chemotherapy in small cell lung cancer patients SDZ ILE 9ud IL-3 study.Cancer Chemother Pharmacol.1996,38(Suppl):389-395
[31]Hofstra LS,Knstensen GB,Willomse PH.et at.Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow'depression during first-line chemotherapy for ovarian carcinoma[J].J Clin Oncol.1998,16(10):3335-3339
[32]Crawford J.Uu D.Erwin R.et al.A phase I trial of recombinant methnoyl human stem cell factor(SCF)in patients with advanced non-mall cell lung carcinoma[J].Proc Am Soc Clin Oncol.1993,12:135-146
[33]Rinechat J.Hersh E.Issel B.et al.Phase I trial of recombinant human interleukin-1β(rhIL-1β),carboplatin and etoposide in patients with solid cancer:southwest oncology group study 8940[J].Cancer Invest.1997,15(5):403-410
[34]钟立业,陈运贤,林伟.血小板减少症治疗的研究进展[J].血栓与止血学,2001,7(4):178-180
[35]Watanabe A,Kakihara T,Yamamoto K,et al.High-dose dexamethasone therapy for a 14-month-old boy with refractory idiopathic thrombocytopenic purpura[J].Acta Paediatr Jpn Jun.1997,39(3):368-370
[36]Wali YA,Al Lamki Z,Shah W,et al.Pulsed high-dose dexamethasone therapy in children with chronic idiopathic thrombocytopenic purpura[J].Pediatr Hematol Oncol.2002,19(5):329-335
[37]Godeau B,Zini JM,Schaefer A,et al.High-dose methylprednisolone is an alternative treatment for adults with autoimmune thrombocytopenic purpura refractory to intravenous immunoglobulins and oral corticosteroids[J].Am J Hematol Apr.1995,48(4):282-284
[38]Smak Gregoor PJH,van Gelder T,van Besouw NM,van der Mast BJ,Uzermans JN,Weimar W.Randomised study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction[J].Transplantation.2000,70(1):143-148
[39]Reiner A.Idiopathic thrombocytopenic purpura[J].Blood,1995,85:351-358
[40]Emilia G,Morselli M,Luppi M,et al.Long-term salvage therapy with cyclosporinA in refractory idiopathic thrombocytopenic purpura.Blood.2002,99(4):1482-1485
[41]Howard J,Hoffbrand AV,Prentice HG,et al,Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura[J].Br J Haematol.2002,117(3):712-715.
[42]沈建咸,郭瑞官,李健,等.四种方案治疗难治性原发性血小板减少性紫疲的疗效[J].福建医学院学报,1996,30(1):69-70
[43]SV Strother,KS Zuckerman,AF LoBuglio.Colchicine therapy for refractory idiopathic thrombocytopenic purpura[J].Arch Intern Med,1984,144(11):2198-2200
[44]Kamiyama M,Yoshimura Y,Chen K,et al.Effect of intravenous immunoglobulin on inhibition of fibrinogen binding to platelets by sera from patients with immune thrombocytopenia[J].Am J Hematol Oct.1993,44(2):77 -84
[45]Semple JW,Allen D,Rutherford M,et al.Anti-D(VinRho SD)treatment of children with chronic autoimmune thrombocytopenic purpura stimulates transient cytokine/chemokine production[J].Am J Hematol Mar.2002,69(3):225-227
[46]刘义.达那唑的免疫调节作用[J].国外医学妇产科学分册,1997,24(1):12
[47]Ahn YS.Efficacy of danazol in hematologic disorders[J].Acta Haematol,1990,84(3):122-129
[48]Godeau B,Oksenhendler E,Bierling P.Dapsone for autoimmune thrombocytopenic purpura[J].Am J Hematol,1993,44(1):70-72
[49]Hernandez F.Dapsone for autoimmune thromboeytopenic purpura[J].Br J Haematol,1995,90(2):473-475
[50]Meeker ND,Goldsby R,Terrill KR,et al.Dapsone therapy for children with immune thrombocytopenic purpura[J].J Pediatr Hematol Oncol,2003,25(2):173-175
[51]Sekreta CM,Baker DE.Interferon alfa therapy in adults with chronic idiopathic thrombocytopenic purpura[J].Ann Pharmacother Oct,1996,30(10):1176-1179
[52]DMci B,Bosnak M,Kara IH,et al.Interferon-alpha therapy in idiopathic thrombocytopenic purpura[J].Pediatr Int,2001,43(6):577-580
[53]Donato H,Kohan R,Piton A,et al.Alpha-interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura[J].J Pediatr Hematol Oncol,2001,23(9):598-603
[54]陈秋生,沈志祥,韩忠朝,等.肝素增强血小板生成素刺激巨核细胞生成[J].中华血液学杂志,1999,20(9):462-464
[55]沈志祥,李军民,王振义,等.肝素治疗慢性特发性血小板减少性紫疲的初步疗效观察[J].中华血液学杂志,1995,16(4):196-197
[56]展昭民,王志平,陈立君,等.玳瑁紫疲宁治疗原发性血小板减少性紫癜的研究[J].中医杂志.1994,35(9):541-543.
[57]靳丽丽,陶淑春,孟根东.紫癜冲剂治疗原发性血小板减少性紫癜78例[J].辽宁中医杂志,1999,26(6):253-254
[58]黄建.自拟消癜饮治疗原发性紫疲86例[J].湖南中医药导报,1998,4(11):26-27
[59]布仁巴圈,孙海山,刘立杰.蒙药血宝丸治疗慢性血小板减少性紫癜30例疗效观察[J].中国民族医药杂志,1998,4(4):8-9
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |